SRPT Nov 2024 180.000 call
| Previous Close | 5.42 |
| Open | 5.42 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 180.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 5.42 - 5.42 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Investor's Business DailySarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
BloombergSarepta Jumps on Broad Approval for Muscular Dystrophy Drug
(Bloomberg) -- Sarepta Therapeutics Inc.’s gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.Most Read from BloombergCar Dealerships Across US Halt Services After CyberattackCDK Tells Car Dealers Their Systems Likely Offline Several DaysPutin’s Hybrid War Opens a Second Front on NATO’s Eastern BorderUnited Airlines Jet Turns Back After Engine
Business WireSarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
CAMBRIDGE, Mass., June 20, 2024--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.
